10-Q: NexGel Q1 2026 Financial Results and Strategic Update

NexGel reports Q1 2026 financial results, highlighting a net loss of $0.9 million and significant capital raising activities to support its Celularity biomaterials acquisition.

Summary

• Reported Q1 2026 revenue of $2.65 million, a 5.6% decrease from $2.81 million in Q1 2025.
• Net loss attributable to stockholders was $0.93 million for the quarter, compared to $0.71 million in the prior year period.
• Operating expenses increased to $2.02 million, driven by higher professional and consulting fees.
• Successfully raised $7.375 million in April 2026 and an additional $1.21 million in May 2026 through private placements of convertible notes.
• Completed the acquisition of Celularity's regenerative biomaterials portfolio for $13.3 million in total consideration.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging quarter characterized by declining revenues and increased losses, though the aggressive capital raising and acquisition activity suggest a high-risk, high-reward strategic pivot.

Positives

• Secured significant new capital through private placements totaling $8.585 million in April and May 2026.
• Expanded product portfolio through the acquisition of Celularity's commercial-stage regenerative biomaterials.
• Maintained a strong working capital position of $2.32 million as of March 31, 2026.
• Growth in Medical Device/Other revenue segment.

Negatives

• Revenue declined by 5.6% year-over-year, primarily due to lower sales in branded consumer products.
• Gross margin compressed to 40.0% from 42.3% in the prior year period.
• Reported a net loss of $0.87 million for the quarter.
• Identified material weaknesses in internal control over financial reporting regarding segregation of duties.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern due to recurring losses and cash usage.
• Dependence on future capital raises to fund operations and strategic acquisitions.
• Potential failure to achieve expected synergies or revenue growth from the Celularity acquisition.
• Concentration risk with key customers, where a few customers account for a significant portion of accounts receivable.
• Inherent risks in the manufacturing process and potential for technological obsolescence.

Future Outlook

Management expects to continue incurring losses in the near term but anticipates that the acquired Celularity business will contribute positive operating cash flows and improve liquidity. The company plans to focus on sales pipeline development, expanding into adjacent industries, and potentially pursuing further strategic acquisitions.

Management Comments

• Management acknowledges substantial doubt about the ability to continue as a going concern.
• Management believes the acquired Celularity business will improve liquidity and support ongoing operations.
• Management is actively working to remediate material weaknesses in internal controls.

Industry Context

StockSavvy.ai notes that NexGel is operating in a highly competitive medical device and consumer health space, where consolidation and strategic licensing are common tactics to scale. The company's pivot toward proprietary branded products and high-margin biomaterials aligns with broader industry trends of moving away from pure-play contract manufacturing.

Comparison to Industry Standards

• Gross margins of 40% are generally competitive for specialized medical manufacturing but lag behind high-margin pharmaceutical or biotech peers.
• The company's reliance on external capital to fund operations is typical for smaller, growth-stage medical technology firms but presents higher risk compared to established industry players.
• The 'roll-up' strategy for consumer brands is a common approach in the health and beauty sector, similar to larger consumer health conglomerates.

Management Changes

Corporate Governance

Legal Proceedings

• Management is not currently aware of any material legal proceedings.

Related Party Transactions

• Outstanding balances due to C.G. Laboratories, Inc. for contract manufacturing and packaging services.
• Outstanding balance due to the CEO of CG Labs.
• Outstanding balance due to Achieving Consulting Excellence, LLC for consulting services.

Stakeholder Impact

• Shareholders face dilution risk from the conversion of notes and potential future equity raises.
• Creditors are impacted by the company's ongoing going concern status and reliance on debt financing.
• Customers may benefit from an expanded product portfolio following the Celularity acquisition.

Next Steps

• Remediate material weaknesses in internal control over financial reporting.
• Integrate the Celularity regenerative biomaterials portfolio.
• Continue development of proprietary medical devices and drug delivery programs.
• Execute sales pipeline expansion in cosmetics and athletic products.

Key Dates

Recommendation

While the company has secured necessary capital and expanded its portfolio, the combination of declining revenue, margin compression, and significant going concern risks warrants a cautious 'hold' until the company demonstrates successful integration of the new assets and a path to profitability.

Keywords

NexGel, NXGL, hydrogel, wound care, biomaterials, contract manufacturing, 10-Q, Celularity